在患有炎症性肠道疾病的患者中,管理新型口服小分子的风险
Malek Ayoub1, Shivani Mattay1, Andres J Yarur2
1Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
新型小分子药物 (SMD) 为炎症性肠病 (IBD) 提供了口服治疗选择. 虽然有效,但这些SMD带有感染和血栓等风险,需要仔细监测患者.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 存在治疗方面的挑战.
- 口服小分子药物 (SMD) 正在成为新的治疗选择.
- 了解SMD的不良事件 (AE) 对患者安全至关重要.
研究的目的:
- 审查与IBD的小分子药物 (SMD) 相关的常见不良事件 (AE).
- 提供关于在SMD治疗前和治疗期间监测AE的建议.
- 为临床医生和患者提供有关IBD新型疗法的安全性概况的信息.
主要方法:
- 关于IBD的小分子药物的最新研究的文献综述.
- 分析与特定SMD相关的报道不良事件.
- 对临床医生进行监测建议的综合.
主要成果:
- 雅克抑制剂 (如托法西提尼布,乌帕达西提尼布) 与实验室异常,感染和血栓栓塞事件有关.
- 对于S1PR激动剂 (如Ozanimod,Etrasimod) 需要密切监测安全性.
- 各种新型SMD显示出可变的疗效,但共享需要监测的潜在不良事件.
结论:
- 虽然IBD的新型SMD有希望,但相关的不良事件需要仔细监测.
- 临床医生必须教育患者了解潜在的风险和益处.
- 积极的监测可以帮助确保这些先进IBD治疗的安全性.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
